Xin yixue (Jul 2023)

Research progress on LEAP-2 and Ghrelin in metabolism-related diseases

  • Li Feng, Huo Yuqi, Zhao Haoliang

DOI
https://doi.org/10.3969/j.issn.0253-9802.2023.07.004
Journal volume & issue
Vol. 54, no. 7
pp. 475 – 479

Abstract

Read online

Recently， liver-expressed antibacterial peptide 2 （LEAP-2） was found to be an endogenous ligand of growth hormone secretin receptor 1α（GHSR1α）， which can antagonize the activation of Ghrelin. Subsequently， it was found that it can reverse the activation of GHSR1α and reduce the basic activity of GHSR1α. This antagonistic relationship not only plays a key role in regulating the secretion of growth hormone， but also plays an important role in regulating food intake， obesity， glucose homeostasis and other complex functions， which is expected to become a novel target for diagnosis and treatment of metabolism-related diseases， such as diabetes mellitus， obesity and cachexia， etc. In this review， the role of LEAP-2 was analyzed in combination with Ghrelin， basic biological function and its role in the incidence and development of metabolism-related diseases were elaborated， and its potential as a therapeutic target was evaluated.

Keywords